Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GENFIT SA    GNFT   FR0004163111

GENFIT SA

(GNFT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
4.918(c) 4.922(c) 4.72(c) 4.72(c) 4.744 Last
268 410 434 127 507 551 317 303 246 559 Volume
+2.03% +0.08% -4.10% 0.00% +0.51% Change
More quotes
Financials
Sales 2020 6,35 M 7,18 M 7,18 M
Net income 2020 -84,5 M -95,5 M -95,5 M
Net cash position 2020 127 M 144 M 144 M
P/E ratio 2020 -2,95x
Yield 2020 -
Sales 2021 5,85 M 6,61 M 6,61 M
Net income 2021 -83,5 M -94,3 M -94,3 M
Net cash position 2021 95,1 M 107 M 107 M
P/E ratio 2021 -2,31x
Yield 2021 -
Capitalization 183 M 207 M 207 M
EV / Sales 2020 8,85x
EV / Sales 2021 15,1x
Nbr of Employees 194
Free-Float 93,4%
More Financials
Company
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich... 
More about the company
Surperformance© ratings of GENFIT SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GENFIT SA
07/10GENFIT : Half-Year Report of Liquidity Contract with Crédit Industriel et Commer..
PU
07/10GENFIT : Half-Year Report of Liquidity Contract with Crédit Industriel et Commer..
GL
07/10GENFIT : Half-Year Report of Liquidity Contract with Crédit Industriel et Commer..
GL
07/07GENFIT : Enhances Board of Directors with Two Strategic Appointments
GL
06/30GENFIT : June 30, 2020 Annual Shareholders Meeting results
GL
06/19GENFIT : Meeting notice of second convocation - Ordinary Meeting of June 30, 202..
PU
06/19GENFIT : Annual Shareholders Meeting on second convening to be held on June 30, ..
GL
06/11GENFIT : June 11, 2020 Ordinary Shareholders' Meeting: Quorum not met on first c..
GL
06/11GENFIT SA : Proxy Statments
CO
06/08GENFIT : Information relating to the shareholders meeting of June 11, 2020
GL
06/08GENFIT : Information relating to the shareholders meeting of June 11, 2020
GL
05/27GENFIT : Statutory auditors' report on the financial statements - Ordinary Share..
PU
05/27GENFIT : Statutory auditors' report on the consolidated financial statements - O..
PU
05/27GENFIT : Publication of the 2019 Universal Registration Document and the 2019 An..
GL
05/27GENFIT : Special Report of the Board of Directors on Stock Options to the Ordina..
PU
More news
News in other languages on GENFIT SA
07/10GENFIT : Half-Year Report of Liquidity Contract with Crédit Industriel et Commer..
07/10GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Indus..
07/10GENFIT : Half-Year Report of Liquidity Contract with Crédit Industriel et Commer..
07/10GENFIT : Half-Year Report of Liquidity Contract with Crédit Industriel et Commer..
07/08Les valeurs à suivre aujourd'hui à la Bourse de Paris Mercredi 8 juillet 2020
More news
Chart GENFIT SA
Duration : Period :
GENFIT SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENFIT SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 10,70 €
Last Close Price 4,72 €
Spread / Highest target 197%
Spread / Average Target 127%
Spread / Lowest Target 5,93%
EPS Revisions
Managers
NameTitle
Pascal Prigent CEO & EVP-Marketing & Development
Jean-François Mouney Chairman
Dean W. Hum Chief Operating Officer
Nathalie Huitorel EVP, Chief Financial & Administrative Officer
Carol L. Addy Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENFIT SA-73.26%207
LONZA GROUP52.43%42 546
CELLTRION, INC.79.28%36 149
SEATTLE GENETICS, INC.52.59%30 180
IQVIA HOLDINGS INC.-7.66%27 247
MODERNA, INC.220.09%24 344